@article{3e2dafd2f38e4817b1b0c3d44ce081c9,
title = "Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy",
abstract = "Targeted radionuclide therapy (TRNT) has proven to be successful in oncology over the last decade (1–5). In TRNT a radionuclide is linked to a molecule that selectively binds to over-expressed receptors of cancer cells, allowing for a targeted approach in cancer therapy. Accumulation of the radiopharmaceutical in tumor tissue delivers toxic levels of radiation directly to the malicious tumor cells minimizing dose given to healthy tissue.",
keywords = "Radiolanthanides, Samarium-153, Theranostics, Targeted radionuclide therapy, Cancer, Nuclear medicine, Mass separated radionuclides, Resonant laser ionization",
author = "{Van de Voorde}, Michiel and Charlotte Duchemin and Heinke Reinhard and Laura Lambert and Eric Chevallay and Thomas Schneider and {Van Stenis}, Miranda and Cocolios, {Thomas Elias} and Thomas Cardinaels and Bernard Ponsard and Maarten Ooms and Thierry Stora and Andrew Burgoyne",
note = "Score=10",
year = "2021",
month = jul,
day = "19",
doi = "10.3389/fmed.2021.675221",
language = "English",
volume = "8",
pages = "1--9",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media SA",
}